Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- 52 Pharmacotherapy of Dystonia
- 53 Anticholinergics in the Treatment of Dystonia
- 54 Tetrabenazine for the Treatment of Dystonia
- 55 Treatment of Dopa-Responsive Dystonia
- 56 Treatment of Paroxysmal Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
54 - Tetrabenazine for the Treatment of Dystonia
from Section VII - Pharmacotherapy for Dystonia
Published online by Cambridge University Press: 31 May 2018
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- 52 Pharmacotherapy of Dystonia
- 53 Anticholinergics in the Treatment of Dystonia
- 54 Tetrabenazine for the Treatment of Dystonia
- 55 Treatment of Dopa-Responsive Dystonia
- 56 Treatment of Paroxysmal Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 272 - 278Publisher: Cambridge University PressPrint publication year: 2018
References
Asher, SW, Aminoff, MJ (1981). Tetrabenazine and movement disorders. Neurology 31:1051–1054.CrossRefGoogle ScholarPubMed
Fasano, A, Bove, F, Lang, AE (2014). The treatment of dystonic tremor: a systematic review. J Neurol Neurosurg Psychiatry 85:759–769.CrossRefGoogle ScholarPubMed
Frank, S, Ondo, W, Fahn, S, Hunter, C, Oakes, D, Plumb, S, Marshall, F, Shoulson, I, Eberly, S, Walker, F, Factor, S, Hunt, V, Shinaman, A, Jankovic, J (2008). A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 31:127–133.CrossRefGoogle ScholarPubMed
Godwin-Austen, RB (1979). The treatment of the choreas and athetotic dystonias. J R Coll Physicians Lond 13:35–38.Google ScholarPubMed
Huntington Study Group (2006). Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:366–372.CrossRefGoogle Scholar
Jankovic, J (1982). Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 11:41–47.CrossRefGoogle ScholarPubMed
Jankovic, J (1995). Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol 18:197–214.CrossRefGoogle ScholarPubMed
Jankovic, J, Beach, J (1997). Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358–362.CrossRefGoogle ScholarPubMed
Jankovic, J, Orman, J (1988). Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 38:391–394.CrossRefGoogle ScholarPubMed
Kazamatsuri, H, Chien, C, Cole, JO (1972). Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 27:95–99.Google Scholar
Kazamatsuri, H, Chien, CP, Cole, JO (1973). Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 130:479–483.Google ScholarPubMed
Kenney, C, Hunter, C, Mejia, N, Jankovic, J (2006). Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 29:259–264.CrossRefGoogle ScholarPubMed
Kenney, C, Hunter, C, Jankovic, J (2007). Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 22:193–197.CrossRefGoogle ScholarPubMed
LeWitt, PA (2013). Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol 36:92–93.CrossRefGoogle ScholarPubMed
Luciano, AY, Jinnah, HA, Pfeiffer, RF, Truong, DD, Nance, MA, LeDoux, MS (2014). Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism Relat Disord 20:1423–1426.CrossRefGoogle ScholarPubMed
Marsden, CD, Marion, MH, Quinn, N (1984). The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 47:1166–1173.Google Scholar
Ondo, WG, Hanna, PA, Jankovic, J (1999). Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 156:1279–1281.CrossRefGoogle ScholarPubMed
Paleacu, D, Giladi, N, Moore, O, Stern, A, Honigman, S, Badarny, S (2004). Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 27:230–233.Google Scholar
Schrader, C, Dengler, R, Dressler, D (2010). Tetrabenazin in der Behandlung hyperkinetischer Bewegungsstörungen. Psychopharmakotherapie 17:85–90.Google Scholar
Soares-Weiser, K, Fernandez, HH (2007). Tardive dyskinesia. Semin Neurol 27:159–169.CrossRefGoogle ScholarPubMed
Swash, M, Roberts, AH, Zakko, H, Heathfield, KW (1972). Treatment of involuntary movement disorders with tetrabenazine. J Neurol Neurosurg Psychiatry 35:186–191.Google Scholar
Watson, MW, Skelton, D, Jamali, F (1988). Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can J Psychiatry 33:11–13.CrossRefGoogle ScholarPubMed